Biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity

Ratul Chowdhury¹ and Costas D. Maranas¹,*¹

¹Department of Chemical Engineering, The Pennsylvania State University, University Park, PA 16802

Corresponding author | Email: costas@psu.edu

Abstract

SARS-CoV-2 is a novel highly virulent pathogen which gains entry to human cells by binding with the cell surface receptor – angiotensin converting enzyme (ACE2). We computationally contrasted the binding interactions between human ACE2 and coronavirus spike protein receptor binding domain (RBD) of the 2002 epidemic-causing SARS-CoV-1, SARS-CoV-2, and bat coronavirus RaTG13 using the Rosetta energy function. We find that the RBD of the spike protein of SARS-CoV-2 is highly optimized to achieve very strong binding with human ACE2 (hACE2) which is consistent with its enhanced infectivity. SARS-CoV-2 forms the most stable complex with hACE2 compared to SARS-CoV-1 (23% less stable) or RaTG13 (11% less stable) while occupying the greatest number of residues in the ATR1 binding site. Notably, the SARS-CoV-2 RBD out-competes the angiotensin 2 receptor type I (ATR1) which is the native binding partner of ACE2 by 35% in terms of the calculated binding affinity. Strong binding is mediated through strong electrostatic attachments with every fourth residue on the N-terminus alpha-helix (starting from Ser19 to Asn53) as the turn of the helix makes these residues solvent accessible. By contrasting the spike protein SARS-CoV-2 Rosetta binding energy with ACE2 of different livestock and pet species we find strongest binding with bat ACE2 followed by human, feline, equine, canine and finally chicken. This is consistent with the hypothesis that bats are the viral origin and reservoir species. These results offer a computational explanation for the increased infectivity of SARS-CoV-2 and allude to therapeutic modalities by identifying and rank-ordering the ACE2 residues involved in binding with the virus.

Introduction

The causative agent of coronavirus disease 2019 (COVID-19) was identified in January 2020 to be a novel β-coronavirus of the same subgenus as SARS-CoV-1. SARS-CoV-2 strain has caused a
dramatically greater number of infections and fatalities and an effective antiviral treatment and vaccine remains elusive to this day. It has been reported that the first step to viral entry is association between the viral spike RBD and human ACE2 protein\(^1\). There have been several structural analyses\(^2,3\) of both SARS-CoV-1 and SARS-CoV-2 binding interactions with human ACE2 (hACE2) but no quantitative assessment of the contribution of different residues in the spike RBD towards tight binding or comparisons with its native receptor ATR1. It has been suggested\(^2,4\) that viral spike binding to hACE2 prevents ATR1 binding with hACE2 but no quantitative comparisons have been drawn. Experimental and computational investigations have focused on the RBD-hACE2 interaction for SARS-CoV-1\(^5\) and CoV-2\(^7\), the role of glycosylated spike residues\(^8\), and the potential impact of the CoV-2’s furin cleavage site\(^6\).

In this study, we first assess the molecular interactions between the three spike RBDs with the hACE2 complex. We also provide a comparative analysis of the most important RBD residues from all three viral spike proteins that drive binding with hACE2. Using the Rosetta binding energy function to score interactions, we find that SARS-CoV-2 outcompetes the human ATR1 surface receptor protein to preferentially bind hACE2 by 35% quantified using the Rosetta binding energy function. A recent study\(^9\) explained interactions between hACE2 and SARS-CoV-1 vs. SARS-CoV-2 RBDs using a homology modeled structure of SARS-CoV-2 RBD and only considering five residues from the spike RBDs. Building on these results, we used an experimentally confirmed atomic scale maps (cryo-EM structures) for the SARS-CoV-1 and CoV-2 RBD in complex with hACE2. Because no experimentally resolved RaTG13-hACE2 complex structure is available, we computationally reconstructed a putative one using flexible protein-protein docking (see Methods). We find that the RBD of SARS-CoV-2 binds hACE2 23% stronger than SARS-CoV-1 and 11% compared to RaTG13 quantified using the Rosetta energy function. Extending this analysis to include non-human ACE2 orthologues, we calculated a descending order of binding strength starting with bats and followed by humans, felines, canines, equines, bovines, and finally poultry. This rank order is consistent with a recent experimental report that finds that mammals especially felines are susceptible to SARS-CoV-2, whereas birds, fish, and reptiles are not\(^10\).

**Results**

**Analysis of human ACE2 in complex with spike RBDs from the three different coronavirus strains**

Rosetta-based energy minimization of the hACE2-RBD complexes with RBDs from SARS-CoV-1, SARS-CoV-2, and RaTG13 reveals that SARS-CoV-2 exhibits the strongest Rosetta binding score (-48.312 ± 3.4 kcal/mol). SARS-CoV-1 and RaTG13 Rosetta binding energy scores with hACE2 are -37.308 ± 2.3 and -43.168 ± 2.1 kcal/mol, respectively. In an uninfected human cell, the ATR1 receptor
binds to ACE2 to form a receptor complex. Upon infection, the coronavirus presents the RBD of its spike protein to the human ACE2 forming an electrostatically-driven association between the two. Our results indicate that hACE2 can bind with either human ATR1 or the viral spike (but not both simultaneously) as the binding domains overlap. hACE2 forms hydrophobic and strong electrostatic (including pi-pi, and cation-pi) interactions with the binding domain of ATR1 with a Rosetta binding energy of 31.4 kcal/mol which is 35% less strong than the one with the SARS-CoV-2 RBD. The CoV-2 RBD maximally co-opts these interactions to gain entry via strong non-covalent attachment (see Figure 1).

To understand the role of the inter-residue interaction network formed during viral entry, we first constructed a contact map depicting all such interactions for the spike-binding interface of unbound hACE2 (see Figure 1). We then computed the changes in this contact map upon binding with the RBD of SARS-CoV-1, SARS-CoV-2, and RaTG13. We observe that SARS-CoV-2 more radically co-opts the original contact map of unbound hACE2 to form a highly stabilized hACE2-RBD interface (see Figure 1).

Figure 1. SARS-CoV-2 RBD causes the greatest disruption to the original intra-residue contacts of hACE2 achieving the strongest-binding complex. Shown in the figure are the residue contact maps of the hACE2 receptor in the unbound state and when bound with the viral spike protein RBDs from SARS-CoV-1, SARS-CoV-2, and RaTG13, respectively. Filled dots (in green) represent electrostatic (i.e., circles) or hydrophobic (i.e., squares) intra-residue contacts within hACE2. Open circles and squares in the bound state of hACE2 with RBD signify the lost intra-residue contacts within hACE2 upon binding with the three spikes. Shown in yellow, pink and cyan filled circles and squares are the inter-residues contacts formed upon binding with the three spike RBDs. Filled circles or
squares in the light blue region show contacts between hACE2 residues (region 1) that are adjacent to the ones (region 2) contacting the spike RBD (region 3). SARS-CoV-2 disrupts and co-opts the most intra-hACE2 residue contacts forming the most residue contacts between hACE2 and RBD. RBD self-stabilizing contact information and weak (long-range) electrostatic interactions (between 4.5Å and 6.0Å) between the spike and hACE2 are not shown in the figure.

We observe that SARS-CoV-2 forms the greatest number of effective hACE2 contacts (11 hydrogen-bonded, eight electrostatic and two hydrophobic) with sixteen RBD residues at the hACE2 binding interface (see Figure 1). For example, SARS-CoV-2 RBD residue Phe456 simultaneously forms a hydrophobic contact with hACE2 residue Thr27 (using the side-chain) and an electrostatic stabilization with hACE2 residue Asp30 (using the backbone) (see Figure 2). The RaTG13 RBD only forms the hydrophobic interaction whereas the SARS-CoV-1 RBD forms neither (see Figure 2). Consequently, a computational alanine scan (see Figure 3) reveals that alanine mutation of this position leads to significant loss of hACE2 binding in both SARS-CoV-2 (~61% reduction) and RaTG13 (~59% reduction) but not in SARS-CoV-1 (only ~12% reduction). The spike protein RBD for SARS-CoV-1 (and RaTG13) are only able to form eight (and eleven) strong electrostatic contacts using seven (and ten) RBD residues, respectively. This does not imply that SARS-CoV-1 and RaTG13 only use these residues to bind to hACE2. More than fifteen additional interface residues either form weak electrostatic contacts or are simply non-interacting. Table 1 lists the hydrogen-bonded interactions between the RBDs and hACE2 along with the corresponding distances. SARS-CoV-2 reforms the original contact map with hACE2 by leveraging 34.1% (15 out of 44) of self-stabilizing contacts around the spike-binding domain to form 21 new complex-stabilizing contacts. SARS-CoV-1 and RaTG13 show weaker attachments as they are able to co-opt only 13.6% and 20.4% contacts, respectively.

Figure 2. Leu443 present in the SARS-CoV-1 spike RBD is aligned with Phe456 present in SARS-CoV-2 and RaTG13. In SARS-CoV-2, Phe456 simultaneously interacts with hACE2 residues Thr27 and Asp30 whereas only the hydrophobic contact is observed in RatG13. In SARS-CoV-1, Leu443 is unable to establish neither the backbone...
electrostatic contact nor the hydrophobic stabilization of the methyl group of Thr27 present in hACE2. The thickness of the dashed lines denotes the strength of interaction.

**In silico alanine scanning to identify spike residues most important for hACE2 binding**

Each one of the hACE2 binding residues from the three viral spike RBDs was computationally mutated to alanine (one at a time) and the resultant hACE2-RBD complexes were energy minimized and scored using the Rosetta energy function. This procedure assesses how important is the identity of the native residues by defaulting them to alanine and observing whether this significantly affects binding. The percent loss of hACE2 binding upon an alanine mutation was used as a proxy score for assessing the importance of each RBD residue in binding and subsequent pathogenesis. The results from the alanine scan study (see Figure 3) reveal that ~90% (19 out of 21) of the hACE2-binding residues of SARS-CoV-2 are important for complex formation. Even a single mutation to alanine of any of these residues lowers the binding score by more than 60%. These results imply that the SARS-CoV-2 RBDs of the spike protein are highly optimized for binding with hACE2. We note that positions Lys417 and Gly502 have one of the strongest impacts on binding (78% and 79% reduction upon mutation to Ala, respectively). This is because they help establish one strong electrostatic contact with Asp30, and three with Gln325, Lys353, and Gly354 (as listed in Table 1). The computational alanine scanning results identify the same three residues Phe486, Gln493, and Asn501 to be important for hACE2 binding as proposed by Wan et al. We find that Phe486, Gln493, and Asn501 each establish three new contacts, consequently their mutation to Ala (even for only one of them) leads to loss of ACE2 binding by more than ~62.5%.
Figure 3. Alanine scan on hACE2 binding residues of spike RBDs of SARS-CoV-2, SARS-CoV-1, and RaTG13 coronavirus. Bars represent the hACE2 Rosetta binding energies upon alanine mutation at the indicated site normalized with respect to binding score prior to mutation. SARS-CoV-2 spike RBD appears to be highly optimized for binding hACE2 as the single mutation to more than 90% of the residues forming the RBD to alanine causes significant reduction in binding energy.

Alanine scanning results of the spike protein RBD of SARS-CoV-1 show less significant penalty to the binding score upon mutation to alanine. Only twelve residues are involved in strong electrostatic coupling with hACE2 residues, out of which six are hydrogen bonded (indicated in Table 1). In summary, alanine scans indicate that SARS-CoV-2 has the highest number of “effectively” interacting residues at the ACE2 binding interface whereas the SARS-CoV-1 spike forms only a few strong hACE2 connectors with a large number of “idle” interface residues (43% - 9 out of 21) which do not affect
hACE2 binding upon mutation to alanine. RatG13 appears to be between the two with 13 strong
electrostatic interactors (61% - 13 out of 21), out of which seven are hydrogen bonded, and only four idle
residues at the interface (i.e., residues Thr484, Leu486, Gly496, and Tyr505).

Table 1. List of hydrogen-bonded contacts between the spike RBDs from (SARS-CoV-1, SARS-CoV-2, and
RaTG13) and hACE2.

| Sequence ID       | Spike residue | hACE2 residue | Distance (Å) |
|-------------------|---------------|---------------|--------------|
| NC_004718_SARS-CoV-1 | Y450         | Q42           | 2.5          |
|                   | Y456         | H34/ D30      | 2.8/ 2.7     |
|                   | N487         | Q24           | 2.0          |
|                   | G496         | K353          | 1.8          |
|                   | T500         | Y41/ D355     | 2.6/ 1.8     |
|                   | G502         | K353          | 1.9          |
| NC_045512_SARS-CoV-2 | Y449         | Q42           | 2.0          |
|                   | Q474         | Q24           | 2.9          |
|                   | Q493         | H34           | 2.8          |
|                   | S494         | D38           | 1.9          |
|                   | T500         | Y41           | 1.8          |
|                   | G502         | K353/ Q325/ G354 | 2.0/ 2.4/ 3.0 |
|                   | Y505         | R393          | 2.1          |
|                   | Q506         | Q325          | 2.0          |
|                   | A475         | S19           | 1.9          |
|                   | N487         | Q24           | 2.3          |
|                   | K417         | D30           | 1.9          |
| MN996532_RaTG13   | K417         | D30           | 1.8          |
|                   | Y473         | T27           | 2.4          |
|                   | N487         | Q24           | 2.1          |
|                   | Y493         | H34           | 2.6          |
|                   | Y498         | Q42           | 1.9          |
|                   | T500         | Y41           | 1.8          |
|                   | G502         | K353          | 1.9          |

Presence of tyrosine and glycine residues in the hACE2 binding domains of these spike proteins

All three viral RBDs are enriched in tyrosine residues. As many as 26.3% (5 out of 19 residues) of the
SARS-CoV-1 RBD residues, 25% (4 out of 16 residues) for SARS-CoV-2, and 29% (5 out of 17
residues) for RaTG13 are tyrosine residues. We have not explored the phylogenetic basis for the presence
of tyrosine residues but they do seem to be important for conferring high binding affinity spike and
hACE2 for both SARS-CoV-2 and RaTG13, as alluded to by the alanine scan results (see Figure 3). In
contrast, the tyrosine residues in SARS-CoV-1 (Tyr442, Tyr475, and Tyr491) only constitute self-
stabilizing electrostatic contacts. We use Figure 4a to explain one representative case of interface
tyrosine residues from all three RBDs: SARS-CoV-1 (Tyr442 and Asn473), SARS-CoV-2 (Tyr473 and
Tyr489), and RaTG13 (Tyr473 and Tyr489).
The SARS-CoV-2 and RaTG13 Tyr473 and Tyr489 backbones, even though present in a loop, are mutually stabilized by hydrogen bonding and the side chains are locked in place by a pi-pi aromatic interaction between the phenyl rings. This enables both of these tyrosine side-chains to form a strong electrostatic contact with the Thr27 side-chain of hACE2. It is thus unsurprising that mutation of either Tyr473 or Tyr489 (in both SARS-CoV-2 and RaTG13) to alanine results in a similar (>58%, respectively as shown in Figure 3) reduction in binding with hACE2. In contrast, in the energy minimized complex of SARS-CoV-1 RBD with hACE2 both Tyr442 and Tyr475 (see Figure 4a) only contribute to internal stability of the spike by forming strong electrostatic contacts with RBD residues Trp476 and Asn473. They are therefore unavailable (or too far > 6.0Å) for binding with the neighboring hACE2 residues.

Figure 4 (a). The role of tyrosine residues in SARS-CoV-2 and RaTG13 RBD is to form strong contacts with hACE2 residues while in SARS-CoV-1 they are primarily responsible for forming stabilizing contacts within the spike and are hence unavailable for hACE2 binding. (b) The role of glycine residues in both all three RBDs is to provide a xGzGx motif for binding hACE2 Lys353 using a strong electrostatic (or cation- interaction). Here, ‘x’ is a polar residue, and ‘z’ a short chain hydrophobic residue (Ile or Val). The glycine residues along with residue ‘z’ offer a hinge to present polar residue ‘x’ for strong electrostatic interactions with hACE2 residue Lys353.

Next, we focus on the role of glycine residues (see Figure 4b) in all three spike RBDs which form important electrostatic contacts with hACE2 as they lead to more than 55% loss of binding (on average) upon mutation to alanine. We chose to study in detail one such representative glycine from all three spike
protein RBDs –Gly488 and Gly490 from SARS-CoV-1 and Gly502 and Gly504 from SARS-CoV-2 and RaTG13.

Interestingly, for all three variants the interaction with the hACE2 residue Lys353 with glycine residues in the spike protein is the same. Atomic coordinates of both these complexes were independently, and experimentally confirmed by Song et al. in 2018 and Wang et al. in 2020 (manuscript unpublished but structure deposited at - www.rcsb.org/structure/6lzg). Both SARS spike RBDs use a combination of a cation-π and a strong electrostatic interaction to bind with Lys353 whereas RaTG13 uses two electrostatic contacts. One electrostatic interaction is mediated by Thr487 in SARS-CoV-1 and Asn501 (and Asp501) in SARS-CoV-2 (and RaTG13). Two glycine residues and a short hydrophobic residue (‘z’ – Val or Ile) brings Thr487, Asn501, and Asp501 for SARS-CoV-1, SARS-CoV-2, and RaTG13, respectively, within strong electrostatic reach of Lys353 while ensuring another cation-π or an electrostatic interaction between Tyr491, Tyr505, and His505 residues, respectively (see Figure 4b). Mutation Y491A for SARS-CoV-1 has no effect on hACE2 binding but Y505A (and H505A) in SARS-CoV-2 (and RaTG13) reduces binding by more than 40%. However, alanine mutation to any of the hinge glycine residues leads to >70% loss of hACE2 binding in all three RBD-hACE2 complexes. Thus, we recover the strong functional motif xGzGx in the spike RBD which is conserved between all three SARS-CoV strains.

Analysis of the three hACE2 binding interfaces (see Figure 5a-c) demonstrate that even though all three spike proteins have a similar number of total interface residues (see Figure 5f), SARS-CoV-2 establishes more hydrogen bonded contacts (see Figure 5g) followed by RaTG13 and SARS-CoV-1. Consequently, SARS-CoV-2 exhibits the strongest Rosetta binding energy with hACE2 (see Figure 5d) calculated using ten unique Rosetta energy minimization trajectories. Interestingly, RaTG13 spike residues occupy the largest number of hACE2 residues resulting in the highest reduction (~14% more than SARS-CoV-2) of solvent accessible surface area (SASA) (see Figure 5e). Nevertheless, the associated Rosetta binding energy is 11.2% less than the one for SARS-CoV-2 which forms overall stronger hydrogen-bonded contacts.
Figure 5. (a-c). hACE2 binding interfaces of the three spike proteins with six hydrogen-bonded contacts from each of them indicated. (d) Rosetta binding energies between spike RBD and hACE2 averaged from ten independent binding energy minimization trajectories. (e) RaTG13 shows the highest reduction of hACE2 solvent accessible surface area (SASA). (f-g) Even though RaTG13 recruits the highest number of interface residues, SARS-CoV-2 forms the most hydrogen-bonded contacts with hACE2. (h) The sequence alignment of the three RBDs is shown and the residues establishing hydrogen bonds with hACE2 are highlighted in cyan.

Competitive hACE2 binding of the spike RBDs and angiotensin receptor (ATR1)

So far, we examined the biophysical characterization of hACE2 binding with the spike protein. However, in an uninfected cell, through the action of the renin angiotensin system (RAS), hACE2 forms a complex with the angiotensin 2 receptor type I (ATR1)\textsuperscript{12}. Due to the lack of an experimentally resolved structure for the hACE2-ATR1 complex, we used protein-protein docking and Rosetta binding energy screening to identify the most stable configuration of the complex. Analysis of the hACE2-ATR1 binding interface reveals 41 hACE2 residues and 26 ATR1 residues at the interface connected by five strong electrostatic contacts and several long range weak electrostatic contacts. We find that eleven SARS-CoV-2 RBD binding residues of hACE2 are shared by the ATR1 binding region. Moreover, the SARS-CoV-2 spike protein binds hACE2 with ~35% better binding score than ATR1 binds hACE2. RaTG13 and SARS-CoV-1 exhibit ~21% and ~5% better Rosetta binding energies, respectively with hACE2 compared to the hACE2-ATR1 complex. They also share only nine and eight residues, respectively with the ATR1
binding interface of hACE2 as opposed to eleven for SARS-CoV-2 (see Figure 6). Rosetta binding calculations therefore suggest that SARS-CoV-2 can more effectively than CoV-1 outcompete the hACE2-ATR1 complex thus possibly facilitating the formation of the hACE2-spike complex. This is in line with the respective Cov-1 vs. Cov-2 infectivities.

Figure 6. hACE2 complexes with ATR1, SARS-CoV-1, SARS-CoV-2, and RaTG13 spike RBDs along with the number of shared hACE2 residues (Venn diagram) at their respective binding regions is shown. Residue positions that are shared between ATR1 and the three spike RBDs (SARS-CoV-1, SARS-CoV-2, and RaTG13) have been listed.

We computationally explored the potentially available margin of improvement for the binding affinity of SARS-CoV-2 with hACE2 using the IPRO\textsuperscript{13} protein design software. We allowed all 21 contacting residues of the RBD of the spike protein to simultaneously mutate. We run two separate design trajectories and, in both cases the best design achieved an approximately 23\% improvement in binding affinity using the Rosetta scoring function. This improvement is less than the difference between the calculated binding scores of SARS-CoV-1 and SARS-CoV-2 implying that SARS-CoV-2 has already achieved most of the theoretically possible binding affinity gain with hACE2 compared to SARS-CoV-1. Interestingly, the network of glycine residues in SARS-CoV-2 is conserved in all redesigned RBDs.

A recent report\textsuperscript{14} analyzes that humans can transfer SARS-CoV-2 to domesticated animals such as dogs, cats, ducks, and chickens in varying degrees. However, animal-to-human transmission has not been observed\textsuperscript{15}. Similar to SARS-CoV-1\textsuperscript{16}, felines are more susceptible to SARS-CoV-2 followed by canines\textsuperscript{17} whereas chickens and ferrets are less susceptible\textsuperscript{17}. The calculated Rosetta binding energies do
not follow the trends ($R^2=0.383$) expected from simply their respective sequence identities with the human ACE2. Interestingly, even though the ACE2 (Uniprot Entry: G1PKW9_MYOLU) of the little brown bat (*Myotis lucifugus*) is quite different from human (similarity 84.5%, identity 66.7%), we predict a stronger Rosetta binding energy (by about ~5.6%). This is due to the formation of nine electrostatic contacts and one pi-pi stacking. Strong binding with bat ACE2 may be a consequence of the SARS-CoV-2 origins. In all other cases, the Rosetta binding energies of ACE2 with the spike protein were at most 78.3% of the one calculated with hACE2. We found that feline ACE2 had the closest (78.3% of hACE2-CoV-2) Rosetta binding energy with the spike compared to other pet or livestock animals.

**Discussion**

In this effort we apply Rosetta binding analysis to gain insight onto possible biophysical factors that may explain the difference in pathogenicity of SARS-CoV-2 in comparison to SARS-CoV-1 and RaTG13. Multiple lines of computational evidence indicate that the spike RBD binds hACE2 through electrostatic attachment with every fourth residue on the N-terminal alpha-helix (starting from Ser19 to Asn53) as the turn of the helix makes these residues solvent accessible. Results from computational models of canine, feline, bovine, equine, and chicken ACE2 in complex with SARS-CoV-2 spike RBD recapitulates infectivity potential observed so far and pinpoint bat ACE2 as the most highly optimized for binding the SARS-CoV-2 spike protein.

**Methods**

We have used experimentally determined coordinates of SARS-CoV-1 and SARS-CoV-2 in complex with ACE2 (PDB accessions: 6ACG\textsuperscript{11} and 6LZG - www.rcsb.org/structure/6lzg, respectively). RaTG13 RBD model was built using the iTasser program\textsuperscript{18}. Similarly, unbound ATR1 structure (PDB: 4YAY\textsuperscript{19}) was also separately downloaded and docked against hACE2 using protein-protein docking scripts from Z-DOCK 3.0\textsuperscript{20}. ZDOCK uses pairwise shape-complementarity, electrostatics, and implicit solvation terms in scoring the docked poses. Implicit solvation treats the water as a dielectric continuum. The rotational sampling interval was set to $10^\circ$. Clustering of the docked poses were done at an 8 Å cutoff. Subsequently, PyRosetta\textsuperscript{21} scripts were written to rank and identify the most stable complexes from each cluster which were then energy-minimized and re-ranked. Finally, the complex which ranked high in stability and binding scores was chosen as the model. An alanine scan was again performed using PyRosetta scripts, where the computational models of the alanine variants were first generated, energy minimized, and hACE2 binding scores computed. The hACE2 interface definitions for each binding partner (RBDs and ATR1) were obtained by feeding the energy minimized protein-protein complexes through the `find_contacts` module of OptMAVEN-2.0\textsuperscript{22}.  

---

\textsuperscript{11} doi: 10.1101/2020.03.30.015891; this version posted May 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
We used the three-dimensional atomic coordinates of the experimentally determined human ACE2 (hACE2) in complex with SARS-CoV-2 spike RBD (PDB id: 6ZLG https://www.rcsb.org/structure/6lzg) as a backbone template to repackage the updated residue side-chains of bat, feline, canine, bovine, equine, and chicken ACE2. A python script was prepared to execute multiple times the iTasser program\textsuperscript{18}. First, a fragment structure assembly was performed using replica-exchange Monte Carlo\textsuperscript{23} followed by clustering of decoy ACE2 structures generated using the SPICKER protocol\textsuperscript{24}. Finally atomic-level backbone and side chain refinement was performed using fragment-guided molecular dynamics simulations (FG-MD)\textsuperscript{25} for 50ns for each structure. All five ACE2s were subsequently docked with the SARS-CoV-2 spike RBD protein whose 3D coordinates were downloaded from the hACE2-spike complex (PDB id: 6LZG).

**Author Contributions**
RC, and CDM conceived, designed, and wrote the study.

**Acknowledgement**
RC thanks Debolina Sarkar for advice on the renin angiotensin system and also editing the paper. This activity was partially enabled by research conducted within the Center for Bioenergy Innovation (DE-SC0018420) and NSF CBET1703274. All simulations were performed on the Institute for Computational and Data Sciences Advanced CyberInfrastructure (ICDS-ACI) high-performance computing (HPC) facility at the Pennsylvania State University.

**Competing Financial Interests**
The authors declare no competing financial interests.

**References**
1. Hoffmann, M. \textit{et al.} SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. \textit{Cell} (2020) doi:10.1016/j.cell.2020.02.052.
2. Shang, J. \textit{et al.} Structural basis of receptor recognition by SARS-CoV-2. \textit{Nature} (2020) doi:10.1038/s41586-020-2179-y.
3. Wang, Q. \textit{et al.} Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. \textit{Cell} (2020) doi:10.1016/j.cell.2020.03.045.
4. Asai, A. \textit{et al.} COVID-19 drug discovery using intensive approaches. \textit{International Journal of Molecular Sciences} (2020) doi:10.3390/ijms21082839.
5. Kuba, K. \textit{et al.} A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. \textit{Nat. Med.} 11, 875–879 (2005).
6. Walls, A. C. et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* (2020) doi:10.1016/j.cell.2020.02.058.

7. Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* (80-. ) (2020) doi:10.1126/science.abb2762.

8. Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific analysis of the SARS-CoV-2 glycan shield. *bioRxiv* (2020) doi:10.1101/2020.03.26.010322.

9. Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *J. Virol.* (2020) doi:10.1128/jvi.00127-20.

10. Lam SD, B. N. et al. SARS-CoV-2 spike protein predicted to form stable complexes with host receptor protein orthologues from mammals, but not fish, birds or reptiles. *bioRxiv* doi.org/10.1101/2020.03.30.015347.

11. Song, W., Gui, M., Wang, X. & Xiang, Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. *PLoS Pathog.* (2018) doi:10.1371/journal.ppat.1007236.

12. Tikellis, C. & Thomas, M. C. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *International Journal of Peptides* (2012) doi:10.1155/2012/256294.

13. Pantazes, R. J., Grisewood, M. J., Li, T., Gifford, N. P. & Maranas, C. D. The Iterative Protein Redesign and Optimization (IPRO) suite of programs. *J. Comput. Chem.* (2015) doi:10.1002/jcc.23796.

14. Chen, H. Susceptibility of ferrets, cats, dogs, and different domestic animals to SARS-coronavirus-2. *bioRxiv* (2020) doi:10.1101/2020.03.30.015347.

15. Xu, J. et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. *Viruses* (2020) doi:10.3390/v120200244.

16. Peiris, J. S. M. & Poon, L. L. M. Severe Acute Respiratory Syndrome (SARS). in Encyclopedia of Virology (2008). doi:10.1016/B978-012374410-4.00780-9.

17. Mallapaty, S. Coronavirus can infect cats - dogs, not so much. *Nature* (2020) doi:10.1038/d41586-020-00984-8.

18. Yang, J. & Zhang, Y. I-TASSER server: New development for protein structure and function predictions. *Nucleic Acids Res.* (2015) doi:10.1093/nar/gkv342.

19. Towler, P. et al. ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis. *J. Biol. Chem.* (2004) doi:10.1074/jbc.M311191200.

20. Mintseris, J. et al. Integrating statistical pair potentials into protein complex prediction. *Proteins Struct. Funct. Genet.* (2007) doi:10.1002/prot.21502.

21. Chaudhury, S., Lysov, S. & Gray, J. J. PyRosetta: A script-based interface for implementing molecular modeling algorithms using Rosetta. *Bioinformatics* (2010) doi:10.1093/bioinformatics/btq007.

22. Chowdhury, R., Allan, M. F. & Maranas, C. D. OptMAVEn-2.0: De novo Design of Variable Antibody Regions Against Targeted Antigen Epitopes. *Antibodies* (2018) doi:10.3390/antib7030023.

23. Swendsen, R. H. & Wang, J. S. Replica Monte Carlo simulation of spin-glasses. *Phys. Rev. Lett.* (1986) doi:10.1103/PhysRevLett.57.2607.

24. Zhang, Y. & Skolnick, J. SPICKER: A clustering approach to identify near-native protein folds. *J. Comput. Chem.* (2004) doi:10.1002/jcc.20011.

25. Zhang, J., Liang, Y. & Zhang, Y. Atomic-level protein structure refinement using fragment-guided molecular dynamics conformation sampling. *Structure* (2011) doi:10.1016/j.str.2011.09.022.